Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
49
IPA Quote, Financials, Valuation and Earnings
Last price:
$1.6800
Seasonality move
:
419.43%
Day range:
$1.7100 - $1.9848
52-week range:
$0.2700 - $2.3173
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.87x
P/B ratio:
4.59x
Volume:
1.4M
Avg. volume:
4.3M
1-year change:
91.21%
Market cap:
$79.6M
Revenue:
$18.2M
EPS (TTM):
-$1.17
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ImmunoPrecise Antibodies has 129.89% upside to fair value with a price target of $4.0000 per share.
IPA vs. S&P 500
-
Over the past 5 trading days, ImmunoPrecise Antibodies has overperformed the S&P 500 by 3.88% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ImmunoPrecise Antibodies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ImmunoPrecise Antibodies revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter ImmunoPrecise Antibodies reported revenues of $4.3M.
Earnings Growth
-
ImmunoPrecise Antibodies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ImmunoPrecise Antibodies reported earnings per share of -$0.46.
Enterprise value:
70.7M
EV / Invested capital:
--
Price / LTM sales:
2.87x
EV / EBIT:
--
EV / Revenue:
4.06x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-10.41x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$8.8M
Return On Assets:
-76.46%
Net Income Margin (TTM):
-193.3%
Return On Equity:
-132.89%
Return On Invested Capital:
-128.72%
Operating Margin:
-53.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $15.5M | $17.5M | $17.4M | $4.6M | $4.3M | |
| Gross Profit | $8.8M | $9.1M | $8.8M | $2.4M | $2.3M | |
| Operating Income | -$20.2M | -$9.9M | -$10.6M | -$2.5M | -$2.3M | |
| EBITDA | -$15.8M | -$7.1M | -$32.4M | -$1.6M | -$16.1M | |
| Diluted EPS | -$0.84 | -$0.41 | -$1.17 | -$0.07 | -$0.46 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.2M | $31.8M | $14.1M | $11.2M | $14.3M | |
| Total Assets | $34.1M | $44.2M | $61.6M | $58.7M | $31.4M | |
| Current Liabilities | $5.7M | $5.6M | $5M | $6.8M | $6.2M | |
| Total Liabilities | $8.9M | $6.9M | $16M | $21.5M | $14.1M | |
| Total Equity | $25.2M | $37.4M | $45.6M | $37.2M | $17.3M | |
| Total Debt | $1.4M | $1M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.5M | -$3.1M | -$5.7M | -$766.4K | -$715.6K | |
| Cash From Investing | -$4.4M | -$684.5K | -$1.1M | $40.1K | -$68.2K | |
| Cash From Financing | $2.3M | -$364.5K | $11.6M | $450.8K | $7.2M | |
| Free Cash Flow | -$15.4M | -$3.6M | -$6.8M | -$646.1K | -$783.8K | |
IPA
Sector
Market Cap
$79.6M
$35.2M
Price % of 52-Week High
75.09%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
-66.54%
-1.01%
1-Year Price Total Return
91.21%
-36.85%
Beta (5-Year)
0.458
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.7869
200-day SMA
Buy
Level
$0.5649
Bollinger Bands (100)
Buy
Level
0.2414 - 1.0614
Chaikin Money Flow
Sell
Level
-565.7K
20-day SMA
Buy
Level
$1.3756
Relative Strength Index (RSI14)
Buy
Level
62.0031
ADX Line
Buy
Level
27.3836
Williams %R
Neutral
Level
-43.8245
50-day SMA
Buy
Level
$0.8954
MACD (12, 26)
Buy
Level
0.5008
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
2.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.371)
Sell
CA Score
(Annual)
Level (-1.4623)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.0947)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
Stock Forecast FAQ
In the current month, IPA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IPA average analyst price target in the past 3 months is $4.0000.
-
Where Will ImmunoPrecise Antibodies Stock Be In 1 Year?
According to analysts, the consensus estimate is that ImmunoPrecise Antibodies share price will rise to $4.0000 per share over the next 12 months.
-
What Do Analysts Say About ImmunoPrecise Antibodies?
Analysts are divided on their view about ImmunoPrecise Antibodies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ImmunoPrecise Antibodies is a Sell and believe this share price will drop from its current level to $3.0000.
-
What Is ImmunoPrecise Antibodies's Price Target?
The price target for ImmunoPrecise Antibodies over the next 1-year time period is forecast to be $4.0000 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IPA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ImmunoPrecise Antibodies is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IPA?
You can purchase shares of ImmunoPrecise Antibodies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ImmunoPrecise Antibodies shares.
-
What Is The ImmunoPrecise Antibodies Share Price Today?
ImmunoPrecise Antibodies was last trading at $1.6800 per share. This represents the most recent stock quote for ImmunoPrecise Antibodies. Yesterday, ImmunoPrecise Antibodies closed at $1.7400 per share.
-
How To Buy ImmunoPrecise Antibodies Stock Online?
In order to purchase ImmunoPrecise Antibodies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 4.92% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 0.03% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 9.69% over the past day.
